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ABSTRACT
Objective: The intent of this study was to determine the efficacy and tolerance of single dose oral
cefixime use in the treatment of pregnant women with endocervical gonococcal carriage.
Methods: A retrospective review of clinic records over a 3 year period identified patients treated
with a single 400 mg dose of cefixme for gonorrhea during pregnancy. Side effects and subsequent
gonococcal carriage were noted.
Results: Pregnant women (n 102) treated with cefixime were reviewed. A cure rate of 95.2%
was found. Side effects were reported in three patients: two had nausea and vomiting and one had
diarrhea.
Conclusions: A single 400 mg oral dose of cefixime was effective for the treatment of gonorrhea
and was well tolerated by the pregnant women. Infect. Dis. Obstet. Gynecol. 5:259-261, 1997.
(C) 1997 Wiley-Liss, Inc.
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onococcal carriage in pregnancy raises concern
for the patient, her unborn child, and her sex-
ual partner. Current treatment recommendations
include intramuscular ceftriaxone and single dose
oral treatment with cefixime, ciprofloxin, or ofloxa-
cin. 1’2 Of oral medications, only cefixime is indi-
cated for pregnant women, e When considering
treatment in pregnancy, the oral cefixime would be
both simpler to administer and painless. Cefixime
appears highly effective. We have used cefiximc
since July 1993, because alternative drugs for use in
pregnancy are not freely available. We present our
experience with cefixime concerning efficacy and
tolerance in 102 patients followed in our practice.
We are unaware of prior reports concerning cefix-
ime use in pregnancy.
SUBJECTS AND METHODS
The reported patients attended a community-
based prenatal and family planning program in an
underserved area between July 1993 and October
1996. Surveillance data previously identified gono-
coccal cervical carriage in just over 10% of prenatal
patients.
3 Patients included in this report were
identified by audit of clinic records.
Cervical swabs were analyzed by direct DNA
assay (Gen-Probe, Inc., San Diego, CA), which was
routinely performed on all obstetric registrants and
repeated at 34 weeks in the author’s clinic. This
test has a sensitivity of 93-99% and a specificity of
99%.4,5 Pregnant women with a positive gonorrheal
screen were offered treatment with 400 mg of ce-
fixime on site and observed for 30 min after this
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oral medication was administered. Patients were
questioned later as to the occurrence of side ef-
fects, including nausea, vomiting, diarrhea, ab-
dominal pain, respiratory difficulty, or skin rash.
Information was obtained by patient recall at a sub-
sequent visit; diaries were not kept. Patients were
instructed to abstain from intercourse until their
sexual partners had completed treatment. Partners
were referred to a sexually transmitted disease
(STD) clinic available to all patients. The occur-
rence of this STD was reported to the State Health
Department. A test of cure was generally obtained
2 weeks after treatment, a time selected to fit with
general clinic activity. A specific study reappoint-
ment was not possible. Patient age, race, parity, and
pregnancy outcome (gestational age and birth
weight) were obtained from chart review and sub-
sequent patient contact. The presence of positive
tests for other STDs at any time during pregnancy
was recorded. These included chlamydia by Gen-
Probe, hepatitis B surface antigen (HBsAg), human
immunodeficiency virus (HIV) antibody confirmed
by Western blot, veneral disease research labora-
tory (VDRL) reaction, and human papilloma virus
(HPV) by Papanicolaou (Pap) smear. These tests
were obtained at the initial visit. VDRL, HIV, and
Gen-Probe for chlamydia and gonorrhea were re-
peated at 34 weeks. Patients with signs or symp-
toms were cultured for genital herpes, but culture
was not routinely obtained. Some patients were




Treated patients were young. Maternal age ranged
from 14 to 37 years, with a median of 18 years.
There were 68 nulliparous patients; 15 had prior
delivery, 12 had 2, and 7 had ->3. Patients were
African-American except for one Caucasian. Treat-
ment was done in 33 patients prior to 14 weeks
gestation. Treatment between 14 and 27 weeks
was done in 47 patients, and 22 patients were
treated at 28 weeks or greater.
Other STDs were frequently identified. Chla-
mydial carriage was found in 59 patients. Concomi-
tant infection was present in 38. Six patients had a
reactive VDRL. Five patients had evidence of
HPV on Pap smear. Three patients were HBsAg
positive. Six treated patients did not have gonor-
rhea at the time of initial obstetric evaluation, but
subsequently acquired this STD.
Cefixime was well tolerated; only two patients,
both of whom also received azithromycin, experi-
enced nausea and vomiting. A third patient receiv-
ing no other antibiotics had diarrhea. No patient
reported a skin rash or respiratory difficulty. Pa-
tients received azithromycin 30 min prior to cefix-
ime in 37 cases. Other antibiotics initiated the
same day include erythromycin (1), metronidazole
(3), clindamycin gel (1), ampicillin (2), cephalexin
(1), and terconazole cream (1).
Treatment was successful in 79 of 83 patients
who had tests of cure. Nineteen patients were ei-
ther delivered (5), underwent pregnancy termina-
tion (2), transferred (2), or lost to follow-up (10).
The four patients (4.8%) who failed therapy had
tests of cure obtained at 20, 29, 39, and 55 days
post-treatment. The patients were 19, 16, 18, and
15 years old, respectively. Reinfection, defined by
a subsequent positive test after the test of cure was
negative, was found in 3 of 44 (6.8%) patients who
were retested during the same pregnancy. For
these 3 patients maternal age was 15, 16, and 17
years. Retreatment with cefixime was done for re-
infection and treatment failure. It was effective in
all 7. Retreatment is not included in efficacy or side
effect data.
Delivery information was sought from review of
records and follow-up contact with patients, when
available. One patient aborted 3 weeks after treat-
ment at 18 weeks gestation. Delivery at <37 weeks
occurred in 10 of 74 patients. Birth weight was
<2,500 g in 15 of 74 patients; only of these was
< 1,500 g.
DISCUSSION
A single 400 mg dose of cefixime was found to be
an effective treatment of Neisseria gonorrhoeae en-
docervical carriage in pregnant women. Side effects
did not pose a major problem. Single dose treat-
ment for pregnant women is not new, but this
orally administered medication is easier to give. We
believe there is little risk for this class B medica-
tion. Our reported cure rate in pregnant women is
similar to that of ceftriaxone (95%). 7
Our failure rate (4.8%) was quite similar to our
demonstrated reinfection rate (6.8%). We suspect
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that many failures were actually reinfection. Both
treatment failure and reinfection appeared in
younger patients; all were teenagers. Programs
similar to ours may need to reemphasize the im-
portance of condom use in the prevention of STDs
combined with appropriate evaluation, treatment,
and follow-up of sexual partners.
Both low birth weight (20.2%) and preterm de-
livery (13.5%) are consistent with the patient popu-
lation served,3 but are causes for concern.
We note that a majority of reported patients also
had cervical carriage of chlamydia during the stud-
ied pregnancy. This may be attributed to the age
(primarily adolescents) and other demographic data
(poverty, inner city, race) in conjunction with an
existing diagnosis of an STD.
For populations similar to ours, we .believe that
initial and late screening for gonorrhea, is appropri-
ate. Treatment with oral cefixime provides an ef-
fective and well-tolerated cure which can be easily
administered.
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